Today’s biologics are providing breakthrough treatment options for the world’s most challenging conditions.

One of the most revolutionary trends driving the biopharmaceutical sector is cell and gene therapy. According to the Journal of Gene Medicine, between 1989 and February 2016, over 2,300 clinical trials were conducted with more than half of them in phase one.

In a recent interview, Dr. Ger Brophy, Executive Vice President, Biopharma Production at Avantor, gave his perspective on this growing segment of the bioprocessing industry as he discussed several key trends and challenges.

Two of the most critical challenges are scalability and manufacturability. If we can manufacture these treatments at scale, can we do so safely? Can we do so at a reasonable cost so the populations that are affected by these diseases can access treatments?

Ger Brophy, Executive Vice President, Biopharma Production

Solutions for cell & gene manufacturing from Avantor

As a supplier for the largest biopharmaceutical manufacturers in the world, we are proud to provide the products, services, solutions and expertise necessary to help our customers quickly and confidently move through the research and production of novel new treatments.

Learn more about our complete offering available through VWR, part of Avantor.